Exelixis, Inc. (NASDAQ:EXEL) Receives $37.59 Average Price Target from Analysts

Exelixis, Inc. (NASDAQ:EXEL) has been given a consensus recommendation of “Moderate Buy” by the twenty ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $37.59.

Several research analysts recently commented on EXEL shares. Stifel Nicolaus increased their price objective on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. Royal Bank of Canada upped their target price on shares of Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Citigroup raised their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $41.00 to $33.00 in a report on Friday, January 24th. Finally, Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $30.00 to $40.00 in a report on Monday, January 27th.

Exelixis Stock Down 0.0 %

Shares of NASDAQ EXEL opened at $37.71 on Friday. The firm has a market cap of $10.55 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company’s 50-day simple moving average is $35.70 and its 200-day simple moving average is $33.09. Exelixis has a 52-week low of $20.14 and a 52-week high of $40.02.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities research analysts anticipate that Exelixis will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now directly owns 341,028 shares in the company, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock valued at $5,177,234 over the last 90 days. 2.85% of the stock is owned by insiders.

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $25,000. Colonial Trust Co SC grew its stake in shares of Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 765 shares in the last quarter. Principal Securities Inc. increased its position in shares of Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares during the period. USA Financial Formulas purchased a new stake in shares of Exelixis during the fourth quarter worth $32,000. Finally, Kestra Investment Management LLC acquired a new stake in shares of Exelixis in the fourth quarter valued at $39,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.